Novel, Dual-Action Peptide for Treament of Type 2 Diabetes
Di-Bait Project ID : 7-2015-3167
Summary of the technology
Project ID : 7-2015-3167
Description of the technology
Life Sciences and Biotechnology
Type 2 Diabetes, Peptide, Insulin, Fatty liver, Glucose.
Current development stage
TRL3 Experimental proof of concept
Based on a provocative working hypothesis, DiBait (DB) has identified the molecular origin of insulin resistance (IR). This, in turn, enables DB designing an 11 a.a. peptide that eliminates IR in animal models.
We envision a short peptide or peptidomimetic molecule that is likely to be packaged in a capsule using appropriate formulation for oral administration to cure type 2 diabetes.
The collaboration with major Pharma companies will help accelerate the drug development process and bring an effective therapy to hundreds of millions of T2D patients around the world